AZ wins European approval for Iressa

It's been a long time coming, but AstraZeneca says that the European Commission has approved its oral cancer drug Iressa. AZ withdrew its EU app in 2005 and resubmitted it in early 2008. In a sign of the growing importance of personalized therapies, the approval is for adults with locally advanced or metastatic non-small cell lung cancer whose tumors have an EGFR mutation. The drug scrambles cellular communications required for tumor growth. Once seen as a potential blockbuster, Iressa stumbled badly when a late-stage trial failed to demonstrate positive results in 2004. Now, though, the therapy could start a comeback. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.